ATE500245T1 - Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs - Google Patents

Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs

Info

Publication number
ATE500245T1
ATE500245T1 AT08785643T AT08785643T ATE500245T1 AT E500245 T1 ATE500245 T1 AT E500245T1 AT 08785643 T AT08785643 T AT 08785643T AT 08785643 T AT08785643 T AT 08785643T AT E500245 T1 ATE500245 T1 AT E500245T1
Authority
AT
Austria
Prior art keywords
cancer
pyridonamide
fak
inhibitors
derivatives
Prior art date
Application number
AT08785643T
Other languages
English (en)
Inventor
Guy Georges
Klaus Kaluza
Matthias Koerner
Ulrike Reiff
Stefan Scheiblich
Der Saal Wolfgang Von
Stefan Weigand
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE500245T1 publication Critical patent/ATE500245T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT08785643T 2007-08-22 2008-08-20 Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs ATE500245T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07016399A EP2065380A1 (de) 2007-08-22 2007-08-22 Pyridonamid-Derivate als Focal-Adhesion-Kinase (FAK) Hemmer und deren Verwendung zur Behandlung von Krebs
PCT/EP2008/006834 WO2009024332A1 (en) 2007-08-22 2008-08-20 Pyridoneamide derivatives as focal adhesion kinase (fak) inhibitors and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE500245T1 true ATE500245T1 (de) 2011-03-15

Family

ID=38924813

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08785643T ATE500245T1 (de) 2007-08-22 2008-08-20 Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs

Country Status (9)

Country Link
US (1) US20110218199A1 (de)
EP (2) EP2065380A1 (de)
JP (1) JP2010536813A (de)
CN (1) CN101784538A (de)
AT (1) ATE500245T1 (de)
CA (1) CA2696197A1 (de)
DE (1) DE602008005326D1 (de)
ES (1) ES2360162T3 (de)
WO (1) WO2009024332A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010140835A2 (ko) * 2009-06-01 2010-12-09 연세대학교 산학협력단 신규한 피리돈 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 암 치료용 약학 조성물
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
JP5937111B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ Ｆａｋ阻害剤
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
US11589583B2 (en) 2013-12-03 2023-02-28 Fmc Corporation Pyrrolidinones herbicides
EP3663282B1 (de) 2013-12-03 2022-05-18 FMC Corporation Pyrrolidinonherbizide
EP3164386B1 (de) 2014-07-02 2020-10-07 FMC Corporation Piperidinon-herbizide
CN107001260B (zh) 2014-12-08 2020-11-10 Fmc公司 3-氧基-3-(芳氨基)丙酸酯、其制备方法、以及其在制备吡咯烷酮中的用途
AU2016246410B2 (en) 2015-04-10 2020-11-05 Fmc Corporation Substituted cyclic amides as herbicides
CN107531658B (zh) 2015-04-27 2021-07-27 Fmc公司 作为除草剂的丁内酯
BR112017021859B1 (pt) 2015-05-12 2022-05-10 Fmc Corporation Composto, composições herbicidas, mistura herbicida e método para o controle do crescimento de vegetação indesejada
JP6869192B2 (ja) * 2015-05-29 2021-05-12 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 除草剤としての置換環状アミド
CA2983759A1 (en) 2015-06-02 2016-12-08 E I Du Pont De Nemours And Company Substituted cyclic amides and their use as herbicides
JP6817287B2 (ja) * 2015-07-21 2021-01-20 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キラルジアリール大環状分子及びその使用
EP3328836B1 (de) 2015-07-31 2021-03-24 FMC Corporation Cyclische n-carboxamid verbindungen verwendbar als herbizide
ES2958741T3 (es) 2016-12-21 2024-02-14 Fmc Corp Herbicidas de nitrona
AU2018239935B2 (en) 2017-03-21 2023-05-18 Fmc Corporation Pyrrolidinones and a process to prepare them
EP3599868A4 (de) 2017-03-21 2020-12-02 FMC Corporation Herbizidmischung, zusammensetzung und verfahren
AR111839A1 (es) 2017-05-30 2019-08-21 Fmc Corp Lactamas 3-sustituidas herbicidas
AR111967A1 (es) 2017-05-30 2019-09-04 Fmc Corp Amidas herbicidas
WO2024105364A1 (en) 2022-11-15 2024-05-23 Curadev Pharma Ltd Heterocyclic inhibitors of cdc-like kinases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
CZ20032615A3 (en) * 2001-03-28 2004-03-17 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
EP1581539A4 (de) * 2003-01-03 2007-09-19 Bristol Myers Squibb Co Neue tyrosinkinase-hemmer

Also Published As

Publication number Publication date
JP2010536813A (ja) 2010-12-02
CN101784538A (zh) 2010-07-21
ES2360162T3 (es) 2011-06-01
WO2009024332A1 (en) 2009-02-26
EP2190834A1 (de) 2010-06-02
DE602008005326D1 (de) 2011-04-14
EP2190834B1 (de) 2011-03-02
US20110218199A1 (en) 2011-09-08
EP2065380A1 (de) 2009-06-03
CA2696197A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
ATE500245T1 (de) Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs
MX2009002010A (es) Derivados de heteroarilo como inhibidores de la proteina cinasa.
ATE499372T1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel
MX2007003104A (es) Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a.
WO2006066913A3 (en) Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors
WO2006066914A3 (en) Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
TW200730502A (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
ATE400570T1 (de) 2,4,6-trisubstituierte pyrimidine als inhibitoren von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
WO2009121535A3 (en) Antiproliferative compounds and therapeutic uses thereof
ATE439361T1 (de) 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
TW200719899A (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
DE602007010038D1 (de) Pyrimidylderivate als proteinkinaseinhibitoren
MX2008011769A (es) Derivados de ftalazinona pirazol, su fabricacion y uso como agentes farmaceuticos.
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
TW200612914A (en) Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200738680A (en) Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents
TW200602329A (en) Novel diazine derivatives, their manufacture and use as pharmaceutical agents
TW200626149A (en) Tricycles, their manufacture and use as pharmaceutical agents
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties